Preferred Label : Allogeneic Tri-functional Anti-CD19 CAR-NK Cells;
NCIt synonyms : Allogeneic CD19-TriCAR-T/SILK; Allogeneic CD19-TriCAR SILK Cells; Allogeneic CD19-TriCAR-T/SILK Cells;
NCIt definition : A preparation of allogeneic natural killer (NK) cells transduced with a retroviral
vector expressing the immunostimulatory cytokine interleukin-15 (IL-15) and encoding
a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA)
cluster of differentiation 19 (CD19) that is coupled to the co-stimulatory domains
cluster of differentiation 28 (CD28, T-cell-specific surface glycoprotein CD28), cluster
of differentiation 137 (CD137; 4-1BB), and the zeta chain of the T-cell receptor (TCR)/CD3
complex (TCRzeta; CD247; CD3zeta); and a blocker for the inhibitory T-cell receptor
programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immunomodulating
and antineoplastic activities. Upon transfusion, the allogeneic tri-functional anti-CD19
CAR-NK cells recognize, bind to and induce selective cytotoxicity in CD19-expressing
tumor cells. IL-15 enhances the cytotoxic effect of the NK cells and the activated
anti-tumor T-cells. The PD-1 inhibitory domain targets and binds to programmed cell
death-1 ligand 1 (PD-L1) expressed on tumor cells, thereby preventing the binding
of the PD-1 on T-lymphocytes to its ligand, PD-L1 on tumor cells. This prevents PD-1/PD-L1-mediated
inhibition of T-lymphocytes and leads to the activation and expansion of T-cells resulting
in a cytotoxic T-lymphocyte (CTL) response against tumor cells, thereby enhancing
the elimination of tumor cells. CD19 antigen is a B-cell specific cell surface antigen
expressed in all B-cell lineage malignancies. The co-stimulatory signaling domains
enhance both proliferation of T-cells and anti-tumor activity.;
NCI Metathesaurus CUI : CL937076;
Origin ID : C157484;
UMLS CUI : C4763651;
Semantic type(s)
- Cell [UMLS semantic type]
- concept_is_in_subset
